Sp1299
UNDERSTANDING ZYMFENTRA: THE FIRST AND ONLY SUBCUTANEOUS INFLIXIMAB OFFERING A NEW THERAPEUTIC APPROACH IN CD AND UC MAINTENANCE
Date
May 21, 2024
Presenter
Northwestern Feinberg School of Medicine
Tracks
Related Products
AGA Farron and Martin Brotman, MD, Lecture — Transforming IBD Care 1: The Biologic Revolution — Past, Present and Future
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…
Farron and Martin Brotman, MD, Lecture — IBD in 2025: Reviewing a Quarter Century of Progress
The landscape of treatment for IBD has evolved significantly over the past two decades. This session will examine advances in our understanding of disease pathogenesis and review treatment paradigm changes…
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
